165 related articles for article (PubMed ID: 8780633)
1. Analysis of p53 serum antibodies in patients with head and neck squamous cell carcinoma.
Bourhis J; Lubin R; Roche B; Koscielny S; Bosq J; Dubois I; Talbot M; Marandas P; Schwaab G; Wibault P; Luboinski B; Eschwege F; Soussi T
J Natl Cancer Inst; 1996 Sep; 88(17):1228-33. PubMed ID: 8780633
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of serum p53 antibodies in patients with resected non-small cell lung cancer.
Laudanski J; Burzykowski T; Niklinska W; Chyczewski K; Furman M; Niklinski J
Lung Cancer; 1998 Dec; 22(3):191-200. PubMed ID: 10048472
[TBL] [Abstract][Full Text] [Related]
3. Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma.
Shimada H; Takeda A; Arima M; Okazumi S; Matsubara H; Nabeya Y; Funami Y; Hayashi H; Gunji Y; Suzuki T; Kobayashi S; Ochiai T
Cancer; 2000 Oct; 89(8):1677-83. PubMed ID: 11042560
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of anti-p53 and anti-KRas circulating antibodies in esophageal cancer patients treated with chemoradiotherapy.
Blanchard P; Quero L; Pacault V; Schlageter MH; Baruch-Hennequin V; Hennequin C
BMC Cancer; 2012 Mar; 12():119. PubMed ID: 22448886
[TBL] [Abstract][Full Text] [Related]
5. p53 mutation and locoregional treatment failure in head and neck squamous cell carcinoma.
Koch WM; Brennan JA; Zahurak M; Goodman SN; Westra WH; Schwab D; Yoo GH; Lee DJ; Forastiere AA; Sidransky D
J Natl Cancer Inst; 1996 Nov; 88(21):1580-6. PubMed ID: 8901856
[TBL] [Abstract][Full Text] [Related]
6. Serum p53 antibodies as a prognostic indicator in oral squamous cell carcinoma.
Yamazaki Y; Chiba I; Ishikawa M; Satoh C; Notani K; Ohiro Y; Totsuka Y; Mizuno S; Kitagawa Y
Odontology; 2008 Jul; 96(1):32-7. PubMed ID: 18661202
[TBL] [Abstract][Full Text] [Related]
7. Serum anti-p53 antibodies and prognosis of patients with small-cell lung cancer.
Rosenfeld MR; Malats N; Schramm L; Graus F; Cardenal F; Viñolas N; Rosell R; Torà M; Real FX; Posner JB; Dalmau J
J Natl Cancer Inst; 1997 Mar; 89(5):381-5. PubMed ID: 9060960
[TBL] [Abstract][Full Text] [Related]
8. Circulating anti-p53 antibodies in esophageal cancer patients.
Kozłowski M; Kovalchuk O; Nikliński J; Chyczewski L; Starosławska E; Ciechański A; Dabrowski A; Niklińska W; Dziegielewski P; Lapuć G; Wallner G; Laudański J
Folia Histochem Cytobiol; 2001; 39 Suppl 2():173-4. PubMed ID: 11820593
[TBL] [Abstract][Full Text] [Related]
9. p53 expressions: predicting recurrence and second primary tumors in head and neck squamous cell carcinoma.
Shin DM; Lee JS; Lippman SM; Lee JJ; Tu ZN; Choi G; Heyne K; Shin HJ; Ro JY; Goepfert H; Hong WK; Hittelman WN
J Natl Cancer Inst; 1996 Apr; 88(8):519-29. PubMed ID: 8606380
[TBL] [Abstract][Full Text] [Related]
10. Perioperative changes of serum p53 antibody titer is a predictor for survival in patients with esophageal squamous cell carcinoma.
Shimada H; Shiratori T; Takeda A; Matsushita K; Okazumi S; Akutsu Y; Matsubara H; Nomura F; Ochiai T
World J Surg; 2009 Feb; 33(2):272-7. PubMed ID: 19052812
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of high serum p53 antibody titers in patients with esophageal squamous cell carcinoma.
Suzuki T; Yajima S; Ishioka N; Nanami T; Oshima Y; Washizawa N; Funahashi K; Otsuka S; Nemoto T; Shimada H
Esophagus; 2018 Oct; 15(4):294-300. PubMed ID: 29959634
[TBL] [Abstract][Full Text] [Related]
12. Implications of p53 alterations and anti-p53 antibody response in head and neck squamous cell carcinomas.
Lavieille JP; Righini C; Reyt E; Brambilla C; Riva C
Oral Oncol; 1998 Mar; 34(2):84-92. PubMed ID: 9682769
[TBL] [Abstract][Full Text] [Related]
13. Serum p53 antibody as a potential tumor marker in extrahepatic cholangiocarcinoma.
Okada R; Shimada H; Otsuka Y; Tsuchiya M; Ishii J; Katagiri T; Maeda T; Kubota Y; Nemoto T; Kaneko H
Surg Today; 2017 Dec; 47(12):1492-1499. PubMed ID: 28508195
[TBL] [Abstract][Full Text] [Related]
14. Changes of serum p53 antibodies and clinical significance of radiotherapy for esophageal squamous cell carcinoma.
Cai HY; Wang XH; Tian Y; Gao LY; Zhang LJ; Zhang ZY
World J Gastroenterol; 2008 Jul; 14(25):4082-6. PubMed ID: 18609695
[TBL] [Abstract][Full Text] [Related]
15. Circulating antibodies against p53 protein in patients with ovarian carcinoma. Correlation with clinicopathologic features and survival.
Angelopoulou K; Rosen B; Stratis M; Yu H; Solomou M; Diamandis EP
Cancer; 1996 Nov; 78(10):2146-52. PubMed ID: 8918407
[TBL] [Abstract][Full Text] [Related]
16. [Diagnostic value of E-cadherin, MMP-9, activated MMP-13 and anti-p53 antibodies in squamous cell carcinomas of head and neck].
Al Kassam D; Alvarez Marcos C; Blanco I; de Los Toyos JR; Llorente JL
Med Clin (Barc); 2007 Dec; 129(20):761-5. PubMed ID: 18093475
[TBL] [Abstract][Full Text] [Related]
17. Titration of serum p53 antibodies in 1,085 patients with various types of malignant tumors: a multiinstitutional analysis by the Japan p53 Antibody Research Group.
Shimada H; Ochiai T; Nomura F;
Cancer; 2003 Feb; 97(3):682-9. PubMed ID: 12548611
[TBL] [Abstract][Full Text] [Related]
18. p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610.
Grignon DJ; Caplan R; Sarkar FH; Lawton CA; Hammond EH; Pilepich MV; Forman JD; Mesic J; Fu KK; Abrams RA; Pajak TF; Shipley WU; Cox JD
J Natl Cancer Inst; 1997 Jan; 89(2):158-65. PubMed ID: 8998185
[TBL] [Abstract][Full Text] [Related]
19. Presence of serum p53 antibodies is associated with decreased in vitro chemosensitivity in patients with esophageal cancer.
Shimada H; Okazumi S; Takeda A; Nabeya Y; Matsubara H; Funami Y; Hayashi H; Gunji Y; Suzuki T; Ochiai T
Surg Today; 2001; 31(7):591-6. PubMed ID: 11495153
[TBL] [Abstract][Full Text] [Related]
20. Serum anti-p53 antibodies and p53 protein status in the sera and tumors from bladder cancer patients.
Morita T; Tachikawa N; Kumamaru T; Nukui A; Ikeda H; Suzuki K; Tokue A
Eur Urol; 2000 Jan; 37(1):79-84. PubMed ID: 10671790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
